Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir

Background: In this study, we aimed to compare the intensive care unit (ICU) admission rate of hospitalized mild/moderate COVID-19 patients treated with hydroxychloroquine (HCQ), favipiravir, and HCQ plus favipiravir. Methods: Single center retrospective designed observational study conducted in Ank...

Full description

Bibliographic Details
Main Authors: Rahmet Guner, Imran Hasanoglu, Bircan Kayaaslan, Adalet Aypak, Esragul Akinci, Hurrem Bodur, Fatma Eser, Ayse Kaya Kalem, Orhan Kucuksahin, Ihsan Ates, Aliye Bastug, Yasemin Tezer Tekce, Zeynep Bilgic, Fahriye Melis Gursoy, Hatice Nisa Akca, Seval Izdes, Deniz Erdem, Emra Asfuroglu, Habibe Hezer, Hatice Kilic, Musa Cıvak, Sibel Aydogan, Turan Buzgan
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:Journal of Infection and Public Health
Subjects:
COVID-19
Treatment
Favipiravir
Hydroxychloroquine
ICU
Online Access:http://www.sciencedirect.com/science/article/pii/S1876034120307735

Internet

http://www.sciencedirect.com/science/article/pii/S1876034120307735

Similar Items